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mapping. Additional polymorphic DNA markers based on repeat sequences were
generated for high-resolution mapping (see http://mouse.ski.mskcc.org/).
Molecular identification of fxo and wim
In a mapping cross of 796 opportunities for recombination, fxo was mapped between
D14Mit84 and D7Mit111. Products from polymerase chain reaction with reverse
transcription (RT–PCR) that were amplified from E10.5 fxo embryos lacked the 87-base-
pair exon 16 of the polaris transcript. Analysis of the genomic sequence surrounding exon
16 identified a T to C mutation in the second nucleotide of intron 16 (downstream of exon
16), which was associated with the skipping of exon 16.
In a mapping cross of 2,600 opportunities for recombination, wim was mapped to a
484-kb interval between D5Ski122 and D5Ski114 (see http://mouse.ski.mskcc.org/). The
wim interval contained 7 known and 14 predicted genes, according to the current genome
assembly. We ruled out four genes (Slc30a3, Ucn, Mpv17 and Gckr) as candidates because
mice lacking these genes survive to adulthood25–28. Three genes were not expressed in mid-
gestation embryos on the basis of RT–PCR analysis of E10.5 RNA. Four predicted genes
were not sequenced because their predicted function seemed completely unrelated to Hh
signalling or neural tube patterning. The complete coding region of the remaining ten
candidate genes was sequenced from RT–PCR products amplified from E10.5 wim (six
independent embryos sequenced) and parental (C57BL/6) embryos. The only sequence
change identified was a T to C substitution in a predicted gene corresponding to five
Ensembl predicted transcripts (ENSMUST00000041444, ENSMUST00000041565,
ENSMUST00000041704, ENSMUST00000031036 and ENSMUST00000041963)
homologous to the full-length rat SLB RNA29. The change was confirmed in genomic DNA
from wim embryos and is not present in expressed sequence tags from other mouse strains.
This gene is expressed broadly at E9.5 and E10.5 and at high levels in the node of E7.5
embryos (data not shown).
We identified structural motifs in Polaris and Wim by SMART (http://smart.embl-
heidelberg.de) and Pfam (http://www.sanger.ac.uk/Software/Pfam/) analysis.
Phenotypic analysis
In situ hybridization and X-Gal staining on whole-mount embryos and
immunofluorescence on frozen sections were done as described14. For scanning electron
microscopy (SEM), we collected embryos at E8.0, fixed them in 2.5% glutaraldehyde in
0.1 M Sorenson’s phosphate for .24 h, and dehydrated them through an ethanol series.
Samples were processed and observed according to standard procedures30.
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The Cdc25A phosphatase is essential for cell-cycle progression
because of its function in dephosphorylating cyclin-dependent
kinases. In response to DNA damage or stalled replication, the
ATM and ATR protein kinases activate the checkpoint kinases
Chk1 and Chk2, which leads to hyperphosphorylation of
Cdc25A1–3. These events stimulate the ubiquitin-mediated pro-
teolysis of Cdc25A1,4,5 and contribute to delaying cell-cycle
progression, thereby preventing genomic instability1–7. Here we
report that b-TrCP is the F-box protein that targets phosphory-
lated Cdc25A for degradation by the Skp1/Cul1/F-box protein
complex. Downregulation of b-TrCP1 and b-TrCP2 expression
by short interfering RNAs causes an accumulation of Cdc25A in
cells progressing through S phase and prevents the degradation
of Cdc25A induced by ionizing radiation, indicating that b-TrCP
may function in the intra-S-phase checkpoint. Consistent with
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this hypothesis, suppression of b-TrCP expression results in
radioresistant DNA synthesis in response to DNA damage—a
phenotype indicative of a defect in the intra-S-phase checkpoint
that is associated with an inability to regulate Cdc25A properly.
Our results show that b-TrCP has a crucial role in mediating the
response to DNA damage through Cdc25A degradation.
We previously showed that the ubiquitin-mediated degradation
of Cdc25A at the exit of mitosis is mediated by the anaphase
promoting complex/cyclosome (APC/CCdh1) ubiquitin ligase
through recognition of a specific KEN box sequence8. We also
showed that a Cdc25A KEN mutant is resistant to APC-mediated
ubiquitination but remains short-lived in interphase cells like the
wild-type protein and is still degraded in response to ionizing
radiation, thereby suggesting that Cdc25A may be targeted for
degradation by a dual mechanism8. Furthermore, degradation of
Cdc25A both in cycling cells and in response to DNA damage
depends on phosphorylation1–4, which is also a requirement for the
efficient recruitment of target proteins to Skp1/Cullin/F-box (SCF)
ubiquitin ligases by F-box proteins9,10, as reported for other cell-
cycle regulators (reviewed in ref. 11).
We previously established that Cdc25A is in complex with Cul1
and Skp1 (ref. 8), which prompted us to examine the possible
involvement of SCF in the degradation of Cdc25A. To achieve this,
we screened several human F-box proteins12,13 for interaction with
Cdc25A. We observed that b-TrCP1 and b-TrCP2 (also known as
Fbw1a and Fbw1b, respectively) were the only F-box proteins
among those tested, namely Fbw2, Fbw4, Fbw5 and Fbw7, that
interacted with Cdc25A in vivo (Fig. 1a and data not shown for Skp2
and Fbl3). As a control, we assessed that the Cul1 subunit was bound
to all of the F-box proteins tested. In a parallel experiment, we
showed that overexpressed Cdc25A coprecipitates with b-TrCP1
and b-TrCP2 (hereafter b-TrCP1/2), but not with Skp2 and Fbw7
(Fig. 1b). Notably, the Cdc25A that co-precipitated with b-TrCP1/2
was hyperphosphorylated, because treatment of the immuno-
complexes with l-phosphatase generated a faster migrating band
of Cdc25A (Fig. 1c).
The Cdc25A amino acid sequence contains a motif, DSGXXXXS
(DSG(X)4S), which is similar to the DSGXXS or DSGXXXS motifs
present in known protein substrates of the SCFb-TrCP complex (refs
14–17 and Fig. 2a). Phosphorylation at both serine residues is
required both for b-TrCP binding and for subsequent substrate
degradation15,18. To assess the contribution of this motif to the
interaction, we mutated Ser 82 and Ser 88 to alanine, either alone to
generate a Cdc25ADSG2£ mutant, or in addition to the preceding
Ser 79 to produce a Cdc25ADSG3£ mutant (Fig. 2a). We then tested
whether these mutated proteins would interact with b-TrCP in
transfected cells.
Replacement of the two DSG(X)4S serines with alanine was
sufficient to abolish Cdc25A interaction with b-TrCP1 (Fig. 2b).
This interaction is probably dependent on phosphorylation on the
DSG(X)4S serine residues. Indeed, a Cdc25A-derived peptide con-
taining phosphoserine residues at positions Ser 82 and Ser 88
(Fig. 2a) associated with in vitro translated b-TrCP1/2, but not
with other F-box proteins tested, whereas the unphosphorylated
peptide did not associate at all (Fig. 2c). We also assessed whether a
failure to interact with b-TrCP would affect the stability of Cdc25A.
We determined the half-life of Cdc25ADSG2£ and Cdc25ADSG3£ and
found that the mutants were considerably more stable than wild-
type Cdc25A (Fig. 2d).
To investigate whether b-TrCP stimulates ubiquitination of
Cdc25A, we carried out an in vitro ubiquitination assay using
partially reconstituted HeLa cell extracts. Addition of recombinant
purified b-TrCP1, but not two other F-box proteins (Skp2 and
Fbw7), stimulated ubiquitination of Cdc25A (Fig. 2e). Ubiquitina-
tion by b-TrCP also required protein phosphorylation, because the
reaction was inhibited by replacing ATP with AMP-PNP, an ana-
logue that allows ubiquitin adenylation by E1 ligase but cannot
function as a protein kinase substrate (Fig. 2f). As a control, AMP-
PNP facilitated APC-dependent ubiquitination, which does not
require substrate phosphorylation (data not shown). These data
support the hypothesis that Cdc25A phosphorylation is required
for b-TrCP-mediated ubiquitination. Notably, b-TrCP1-mediated
ubiquitination of Cdc25ADSG3£ was greatly affected as compared
with wild-type Cdc25A (Fig. 2g). Together, these data indicate that
phosphorylation on Ser 82 and Ser 88 is required for efficient
recruitment of Cdc25A by b-TrCP and its subsequent degradation.
We used a series of siRNA experiments to assess further the role of
b-TrCP in controlling the subcellular abundance of Cdc25A. Asyn-
chronously growing cells were transiently transfected with an siRNA
oligonucleotide targeting both b-TrCP1 and b-TrCP2 genes and
analysed for steady-state amounts of Cdc25A. Efficient silencing of
b-TrCP1/2 caused a considerable accumulation of Cdc25A as
compared with mock-transfected cells (Fig. 3a). No substantial
changes were observed in Cdc25A messenger RNA (Fig. 3a).
We then tested the effect of silencing b-TrCP gene expression at
various stages of the cell cycle. Cells that were mock-transfected or
transfected with b-TrCP1/2 siRNA were synchronized by double-
Figure 1 Cdc25A interacts with b-TrCP1 and b-TrCP2 in vivo. a, HeLa cells were
transfected with the indicated Flag–tagged F-box protein constructs. F-box proteins were
immunoprecipitated from extracts with an anti-Flag resin and immunocomplexes were
blotted with antibodies specific for Cul1, Cdc25A and Flag. b, HeLa cells were co-
transfected with a vector expressing His–Cdc25A plus the indicated Flag-tagged F-box
protein constructs. Immunocomplexes were analysed as in a. WCE, whole-cell extract.
Asterisk indicates the position of the IgG heavy chain (b-TrCP2 protein overlaps with IgG).
c, Cdc25A bound to b-TrCP proteins is phosphorylated. Immunocomplexes obtained by
b-TrCP1 immunoprecipitation were treated with l-phosphatase and analysed for
Cdc25A.
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thymidine treatment, released from G1/S arrest in the presence of
nocodazole and analysed over time for Cdc25A. As they progressed
through S phase, cells treated with b-TrCP1/2 siRNA showed a
substantial accumulation of Cdc25A as compared to mock-
transfected cells, as well as a failure to degrade the APC inhibitor
Emi1 (also known as Fbx5), a target of b-TrCP in early mitosis
(refs 19, 20 and Fig. 3b).
To analyse the kinetics of Cdc25A expression at mitotic exit and
in G1 phase, mock-transfected or cells transfected with b-TrCP1/2
siRNA were synchronized by nocodazole treatment, released from
the mitotic block and analysed over time for Cdc25A. Cells
transfected with b-TrCP1/2 siRNA had substantially more
Cdc25A at mitosis than did mock-transfected cells, but similar to
control cells they proceeded normally into G1 phase and degraded
both Cdc25A and cyclin B1, albeit with slower kinetics (Fig. 3c).
This behaviour is probably caused by an increase in Emi1 in cells
transfected with b-TrCP siRNA19,20, resulting in an indirect up-
regulation of Cdc25A through inhibition of Cdh1 at the exit of
mitosis21.
We directly compared the amounts of Cdc25A in mock-
transfected and cells transfected with b-TrCP1/2 and Emi1 siRNA
at different time points (Fig. 3b, c, right). Elimination of b-TrCP
caused an accumulation of Cdc25A in all cell-cycle phases apart
from G1 (Fig. 3c, T6). As a control, we verified that elimination of
Figure 3 b-TrCP controls Cdc25A abundance during progression of S phase. a, HeLa
cells were mock-transfected or transfected with b-TrCP1 and b-TrCP2 siRNA
oligonucleotides. Expression of Cdc25A and b-TrCP1/2 (analysed by immunoblotting and
quantitative PCR) is shown. b, Cells transfected as indicated were synchronized by
double-thymidine block and released in nocodazole-containing medium. Cells were
collected at the indicated time points, lysed and immunoblotted for Cdc25A, Emi1 and
cyclin A. Samples collected at the T0, T6 an T12 time points were aligned for a direct
comparison of Cdc25A expression. c, Cells transfected as indicated were synchronized by
nocodazole treatment and released in drug-free medium. Cells were analysed for
Cdc25A, Emi1 and cyclin B1 as in b. d, Cells transfected with a vector expressing
Flag-tagged wild-type Cdc25A or a Cdc25AKEN2 mutant were subjected to RNA
interference and analysed for overexpression of Cdc25A.
Figure 2 Interaction with b-TrCP protein through a phosphorylated DSG motif is required
for Cdc25A degradation and polyubiquitination. a, Alignment of DSG motifs identified in
known b-TrCP substrates. Serine-to-alanine mutations in the DSG motif of Cdc25A are
boxed. b, Vectors expressing His-tagged Cdc25ADSG2£ and Cdc25ADSG3£ were
coexpressed with Flag–b-TrCP1 in HeLa cells, and anti-Flag immunocomplexes were
blotted for Cdc25A. c, Immobilized Cdc25A-derived peptides, with or without
phosphorylation on Ser 82 and Ser 88 (a), were incubated with [35S]methionine-labelled
in vitro translated F-box proteins (IVT) and analysed by autoradiography. d, HeLa cells
were transfected with the indicated Flag-tagged constructs and analysed for Cdc25A
expression after cycloheximide (CHX) treatment. e, [35S]methionine-labelled in vitro
translated Cdc25A was incubated with HeLa cell extract enriched with the indicated
Skp1–F-box protein complexes and analysed by autoradiography. f, The ATP analogue
AMP-PNP was used in the ubiquitin ligation reaction. g, b-TrCP-mediated ubiquitination
of wild-type Cdc25A and the Cdc25ADSG3£ mutant.
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Emi1 did not affect the expression of Cdc25A protein. We also
observed that the Cdc25AKEN2 mutant, which is not degraded by
APC/CCdh1, also accumulated in cells transfected with b-TrCP1/2
siRNA (Fig. 3d). Together, these data indicate that b-TrCP-mediated
degradation of Cdc25A may occur throughout S and G2, and that
this event is independent of the release of the Emi1-mediated
inhibition of Cdh1.
To examine whether b-TrCP proteins are involved in the ubiqui-
tin-mediated degradation of Cdc25A in response to DNA damage,
cells transfected with b-TrCP1/2 siRNA were treated with ionizing
radiation and analysed for Cdc25A abundance. Cells with reduced
b-TrCP1/2 showed an increase in Cdc25A as compared with mock-
transfected and Cdh1-depleted cells, which were used as a negative
control. Notably, ionizing radiation resulted in an accumulation of
slow-migrating, hyperphosphorylated Cdc25A species (Fig. 4a, b).
Furthermore, the half-life of Cdc25A in S-phase-synchronized and
b-TrCP1/2-depleted cells was extended and remained unmodified
in cells treated with ionizing radiation as compared with untreated
cells (Fig. 4b).
To establish a role for b-TrCP in the Cdc25A-mediated DNA
damage response, we examined whether interfering with b-TrCP
expression would result in a defect in the temporal inhibition of
DNA synthesis. Radioresistant DNA synthesis (RDS), a phenotype
indicative of a defective intra-S-phase checkpoint, occurs in cells
deficient for ATM and Chk2, two upstream negative effectors of
Cdc25A abundance1,22. We checked for the integrity of the intra-S-
phase checkpoint in cells transfected with b-TrCP siRNA by asses-
sing their rate of DNA synthesis after treatment with ionizing
radiation. Whereas mock-transfected cells showed an inhibition
of DNA synthesis of about 40–50% after ionizing radiation, b-
TrCP1/2-depleted cells showed an inhibition of roughly 20%,
consistent with an RDS phenotype (Fig. 4c). This effect was
dependent on an accumulation of Cdc25A caused by b-TrCP
inhibition, given that cells depleted for both b-TrCP and Cdc25A
rescued the RDS phenotype.
Using a polyclonal antibody raised against the phosphorylated
DSG motif of Cdc25A (anti-phosphoS82/S88) and phosphopeptide
mapping, we detected Cdc25A phosphorylation at the DSG motif in
cycling cells (Supplementary Figs 1 and 2). DSG phosphorylation
was stimulated on treatment with ionizing radiation (Fig 4d). It
therefore seems that Cdc25A is phosphorylated at the DSG motif in
cycling cells and that this process is enhanced on DNA damage.
Indeed, expression of the Cdc25ADSG2£ mutant hampered Cdc25A
degradation on treatment with ionizing radiation (Fig 4e).
Cdc25A is phosphorylated on specific serine residues by the Chk1
protein kinase in cycling cells and by both Chk1 and Chk2 in
checkpoint activated cells3, and disruption of the Chk1/Cdc25A
pathway abrogates S and G2 checkpoints induced by ionizing
radiation2,3. Combined mutation of these residues confers stability
to the protein, suggesting that phosphorylation at several sites
contributes to Cdc25A degradation in vivo3. These findings might
indicate that, as in the recognition of Sic1 by Fbw7 (ref. 23), multiple
phosphorylation events on the target protein enhance its interaction
with the F-box protein and stimulate its polyubiquitination24.
For Cdc25A, we found that whereas the Cdc25ADSG2£ mutant failed
to form complexes in vivo with b-TrCP1, Skp1 or Cul1, none of the
Chk1/2 phosphorylation site mutants was impaired in binding these
SCF components (Fig. 4f). The finding that the DSG motif is
required for b-TrCP binding (Fig. 4f) and for b-TrCP-dependent
ubiquitination (Fig. 2g) implies that efficient Cdc25A recognition
by b-TrCP minimally requires two phosphorylation sites in
Cdc25A. This is in agreement with the three-dimensional structure
of a b-TrCP1–Skp1–b-catenin complex25. Phosphorylation on ser-
ine residues other than those in the DSG motif3 might stimulate the
degradation of Cdc25A by facilitating an interaction with additional
components of the SCF complex, or by enhancing the ability of SCF
to catalyse polyubiquitination.
We have shown a requirement for b-TrCP proteins in regulating
Cdc25A ubiquitination in S phase and on treatment with ionizing
radiation. Notably, a gain-of-function mutation in the cdc25 gene of
Caenorhabditis elegans results in deregulated hyperproliferation of
intestinal cells26. The encoded mutated protein carries a serine-to-
phenylalanine substitution in a putative DSG consensus. Given the
fact that mutations in ATM and ATR, which are upstream negative
effectors of Cdc25A, are common in cancer22,27, an assessment of the
occurrence of activating mutations in the Cdc25A gene and/or
inactivating mutations in the b-TrCP genes in normal and tumour
tissues should be warranted. A
Methods
Cell culture, synchronization and transfection
Cell culture, cell synchronization and transfection protocols were done as described8.
Figure 4 b-TrCP is required for degradation of Cdc25A induced by ionizing radiation in
the intra-S-phase checkpoint. a, HeLa cells were mock-transfected or transfected with
b-TrCP or Cdh1 siRNA and after 48 h were exposed to ionizing radiation (10 Gy). Cdc25A
protein is shown at low and high exposure. b, siRNA-transfected S-phase cells were
exposed to ionizing radiation, and the half-life of Cdc25A was analysed by cycloheximide
(CHX) treatment. c, Percentage of DNA synthesis, normalized against mock-transfected
non-irradiated cells, was assessed in mock-transfected cells and in cells transfected with
b-TrCP1/2 or b-TrCP1/2 plus Cdc25A siRNA, 90 min after ionizing radiation treatment.
d, HeLa cells overexpressing Flag–Cdc25A were irradiated with 10 and 20 Gy in the
presence of the proteasome inhibitor MG132 and collected at the indicated time points
after irradiation. Immunoprecipitated Cdc25A was immunoblotted with a purified anti-
phosphoS82/S88 antibody. e, U2OS cells stably expressing wild-type Cdc25A or
Cdc25ADSG2£ were mock-treated or treated by ionizing radiation. f, Flag-tagged Cdc25A
immunocomplexes were immunoblotted for Cdc25A, Cul1, Skp1 and b-TrCP1.
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Plasmids
Flag- and His-tagged Cdc25A mutants were generated using the QuickChange Site-
directed Mutagenesis kit (Stratagene). We verified all constructs by DNA sequencing.
Immunoblotting, immunoprecipitation and phosphatase treatment
Immunoblotting and immunoprecipitation were done essentially as described8, with the
following antibodies: anti-Cdc25A (F6, Santa Cruz Biotech); anti-Flag (M2, Sigma); anti-
Cul1 (Zymed); anti-cyclinB1 (GNS1, Santa Cruz Biotech); anti-cyclinA (H-432, Santa
Cruz Biotech); anti-Myc (9E10, Santa Cruz Biotech); anti-vinculin (Sigma); anti-Skp1
(1C10F4, Zymed); anti-b-TrCP1 (M.P.’s polyclonal serum); anti-b-TrCP2 (N-15, Santa
Cruz Biotech); Anti-Emi1 antibodies were provided by P. K. Jackson (Stanford Univ.
School of Medicine), and anti-Cdh1 monoclonal antibodies were supplied by K. Helin
(European Inst. Oncology).
For phosphatase treatment, 500 units of l protein phosphatase (New England Biolabs)
was added to b-TrCP immunocomplexes in the presence of MgCl2 for 30 min at 30 8C.
Peptide-binding assay
We obtained two peptides corresponding to the amino acid sequence
TDSGFCLDSPGPLD of human Cdc25A (Eurogentec), one of which double-
phosphorylated on serine residues. The peptides were coupled to agarose beads using the
Aminolink kit (Pierce). Coupled Cdc25A peptides (10 mg) were incubated with
[35S]methionine-labelled in vitro translated b-TrCP1/2 obtained by the TNT-coupled
Reticulocyte Lysate system (Promega) in the presence of 5 mCi of [35S]methionine
(Amersham Biosciences). We washed agarose beads with RIPA buffer and assayed binding
by SDS–PAGE followed by autoradiography.
In vitro ubiquitination assay
Ubiquitin ligation was determined essentially as described28 by using [35S]methionine-
labelled in vitro translated Cdc25A. Baculovirus b-TrCP1, Skp2 or Fbw7 were all
coexpressed with His6–Skp1, purified by nickel-agarose chromatography and added in
roughly similar amounts to the reaction.
siRNA
We purchased Cdh1 (ref. 8), b-TrCP1/2 (refs 19, 20), Emi1 (ref. 21) and Cdc25A (ref. 2)
21-base-pair siRNA oligonucleotides (Dharmacon Research). Cells were transfected with
siRNA duplexes by using Oligofectamine (Invitrogen) according to the manufacturer’s
instructions.
Radio-resistant DNA synthesis assay
Cells were transfected with siRNA duplexes, and after 4 h were labelled for 24 h with
20 nCi ml21 [14C]thymidine (Amersham Biosciences) and then incubated in non-
radioactive medium for another 24 h. Cells were irradiated with 10 Gy, incubated for
90 min at 37 8C, and pulse-labelled with 5 mCi ml21 [3H]thymidine (Amersham
Biosciences) for the last 20 min. The medium was removed and the cells were washed twice
with PBS, once with 5% trichloracetic acid and twice with 100% ethanol, and then lysed
with 200 ml of buffer containing 1% SDS and 10 mM NaOH. We assayed 150-ml aliquots in
a liquid scintillation counter. The resulting ratios of 3H counts per min to 14C counts per
min represented a measure of the DNA synthesis.
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The ecdysteroid hormones coordinate the major stages of insect
development, notably moulting and metamorphosis, by binding
to the ecdysone receptor (EcR); a ligand-inducible nuclear tran-
scription factor1,2. To bind either ligand or DNA, EcR must
form a heterodimer with ultraspiracle (USP), the homologue of
retinoid-X receptor3–5. Here we report the crystal structures of
the ligand-binding domains of the moth Heliothis virescens
EcR–USP heterodimer in complex with the ecdysteroid ponas-
terone A and with a non-steroidal, lepidopteran-specific agonist
BYI06830 used in agrochemical pest control. The two structures
of EcR–USP emphasize the universality of heterodimerization
as a general mechanism common to both vertebrates and
invertebrates. Comparison of the EcR structures in complex
with steroidal and non-steroidal ligands reveals radically differ-
ent and only partially overlapping ligand-binding pockets that
letters to nature
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